"If the DSMB reports that the clinical trial is
Post# of 155677
(Total Views: 558)
Posted On: 10/20/2020 7:55:05 AM
"If the DSMB reports that the clinical trial is likely to meet its endpoint and that they should continue the trial, CytoDyn will likely immediately apply for Emergency Use Authorization from the FDA."
From Zerohedge^^^
So maybe the will or did apply for EAU?
I know that alone can slow enrollment so dboutful but couldn’t it also get us exposure, maybe it actually speeds up enrollment?
I don’t see how this can’t happen still. Makes sense to do it. Then again tho is just imo...
From Zerohedge^^^
So maybe the will or did apply for EAU?
I know that alone can slow enrollment so dboutful but couldn’t it also get us exposure, maybe it actually speeds up enrollment?
I don’t see how this can’t happen still. Makes sense to do it. Then again tho is just imo...
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com